Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Crossbow Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | CBX-250Phase 1 · Acute Myeloid Leukemia | Jan 2027CBX-250 · Phase 1 |
 Cullgen (Shanghai),IncPrivate | 1 asset: 1 Ph 1 | CG009301Phase 1 · Acute Myeloid Leukemia | 30 Dec 2027CG009301 · Phase 1 |
 CurisCRIS · | 1 asset: 1 Ph 2 | EmavusertibPhase 2 · Acute Myeloid Leukemia | Nov 2027Emavusertib · Phase 2 |
 CybinHELP · Nasdaq | 1 asset: 1 Ph 3 | CYB003Phase 3 · Major Depressive DisorderPartial signal | 7 Jun 2027CYB003 · Phase 3 |
 Cyclarity TherapeuticsPrivate | 1 asset: 1 Ph 1 | UDP-003Phase 1 · Atherosclerotic Cardiovascular Disease | 30 Dec 2026UDP-003 · Phase 1 |
| 1 asset: 1 Ph 1 | ISC-hpNSCPhase 1 · Parkinson's DiseaseWeak signal | None on record | |
 CytoDynCYDY · OTCQB | 1 asset: 1 Ph 3 | LeronlimabPhase 3 · HIVPartial signal | Jan 2028Leronlimab · Phase 2 |
| 1 asset: 1 Ph 1 | SDT-M001Phase 1 · Non-Small Cell Lung Cancer | 26 Jun 2027SDT-M001 · Phase 1 | |
| 1 asset: 1 Ph 2 | CTS2190Phase 1/2 · Non-Small Cell Lung Cancer | None on record | |
 D&D PharmatechPrivate | 1 asset: 1 Ph 2 | DD01Phase 2 · ObesityPartial signal | None on record |
 DEKA BiosciencesPrivate | 1 asset: 1 Ph 1 | DK210Phase 1 · Non-Small Cell Lung Cancer | None on record |
 DalCor PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | DalcetrapibPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | Aug 2027Dalcetrapib · Phase 3 |
 DebiopharmPrivate | 1 asset: 1 Ph 2 | Debio 1562MPhase 1/2 · Acute Myeloid Leukemia | None on record |
Debiopharm International SAPrivate | 1 asset: 1 Ph 2 | Debio 0123Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | Dec 2027Debio 0123 · Phase 1 |
 Definium TherapeuticsDFTX · Nasdaq | 1 asset: 1 Ph 3 | Lysergide tartrate (LSD)Phase 3 · Major Depressive DisorderPartial signal | Sep 2027Lysergide tartrate (LSD) · Phase 3 |
 Denovo BiopharmaPrivate | 1 asset: 1 Ph 2 | LiafensinePhase 2 · Major Depressive DisorderReliable signal | None on record |
 Dermavon HoldingsPrivate | 1 asset: 1 Ph 3 | CMS-D001Phase 2/3 · Psoriasis | 31 Jan 2027CMS-D001 · Phase 2 |
 Desitin Arzneimittel GmbHPrivate | 1 asset: 1 Ph 3 | Piribedil (Clarium)Phase 3 · Parkinson's DiseasePartial signal | None on record |
 DeuterOncologyPrivate | 1 asset: 1 Ph 1 | DO-2Phase 1 · Non-Small Cell Lung Cancer | Sep 2027DO-2 · Phase 1 |
 DexTech Medical ABDEX · Spotlight Stock Market | 1 asset: 1 Ph 2 | ODX (Osteodex)Phase 1/2 · Multiple Myeloma | None on record |
 DiaMedica TherapeuticsDMAC · Nasdaq | 1 asset: 1 Ph 3 | DM199Phase 2/3 · Acute Ischemic Stroke | Dec 2026DM199 · Phase 2/3 |
 Direct BiologicsPrivate | 1 asset: 1 Ph 3 | ExoFloPhase 3 · Ulcerative ColitisWeak signal | Jun 2027ExoFlo · Phase 2 |
| 1 asset: 1 Ph 2 | HEC88473Phase 2 · ObesityPartial signal | None on record | |
 Dracen PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | DRP-104Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record |
 Draig TherapeuticsPrivate | 1 asset: 1 Ph 2 | DT-101Phase 2 · Major Depressive Disorder | May 2027DT-101 · Phase 2 |
 Dren BioPrivate | 1 asset: 1 Ph 1 | DR-0202Phase 1 · Non-Small Cell Lung Cancer | Jul 2027DR-0202 · Phase 1 |
 EHL BioPrivate | 1 asset: 1 Ph 3 | ADSTEMPhase 3 · Atopic Dermatitis | Jun 2029ADSTEM · Phase 3 |
 ERX PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | ERX1000Phase 2 · ObesityPartial signal | May 2027ERX1000 · Phase 2 |
| 1 asset: 1 Ph 3 | CerebrolysinPhase 3 · Alzheimer's DiseasePartial signal | None on record | |
| 1 asset: 1 Ph 2 | YKST02Phase 2 · Multiple Myeloma | None on record | |
| 1 asset: 1 Ph 2 | EDP167Phase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | Nov 2027EDP167 · Phase 2 | |
 Edgewood Oncology Inc.Private | 1 asset: 1 Ph 1 | BTX-A51Phase 1 · Acute Myeloid Leukemia | None on record |
 Editas Medicine, Inc.EDIT · Nasdaq | 1 asset: 1 Ph 2 | EDIT-301Phase 1/2 · Severe Sickle Cell Disease | None on record |
 EicOsis Human Health, Inc.Private | 1 asset: 1 Ph 2 | EC5026Phase 1/2 · Parkinson's Disease | Dec 2026EC5026 · Phase 1/2 |
 Eikon TherapeuticsEIKN · Nasdaq | 1 asset: 1 Ph 3 | EIK1001Phase 2/3 · Non-Small Cell Lung Cancer | Dec 2026EIK1001 · Phase 2 |
 Elixiron ImmunotherapeuticsPrivate | 1 asset: 1 Ph 2 | EnrupatinibPhase 2 · Alzheimer's Disease | Dec 2026Enrupatinib · Phase 2 |
| 1 asset: 1 Ph 2 | ES102Phase 2 · Non-Small Cell Lung Cancer | 28 Feb 2027ES102 · Phase 2 | |
 Emmaus Life SciencesEMMA · OTCQB | 1 asset: 1 approved | Approved assets only | None on record |
 Empros PharmaPrivate | 1 asset: 1 Ph 2 | EMP16Phase 2 · ObesityReliable signal | None on record |
 Encoded Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | ETX101Phase 1/2 · Epilepsy | Jan 2028ETX101 · Phase 1/2 |
 EncuraGenPrivate | 1 asset: 1 Ph 1 | (PEG)-BHD1028Phase 1 · Obesity | None on record |
| 1 asset: 1 Ph 2 | ENERGI-F705Phase 2 · Parkinson's Disease | 1 Jan 2030ENERGI-F705 · Phase 2 | |
 Engrail TherapeuticsPrivate | 1 asset: 1 Ph 1 | ENX-104Phase 1 · Major Depressive DisorderPartial signal | None on record |
 Enliven TherapeuticsELVN · Nasdaq | 1 asset: 1 Ph 1 | ELVN-001Phase 1 · Chronic Myeloid Leukemia | Dec 2027ELVN-001 · Phase 1 |
 Enlivex TherapeuticsENLV · Nasdaq | 1 asset: 1 Ph 2 | AllocetraPhase 2 · Osteoarthritis | Feb 2027Allocetra · Phase 2 |
 Enterin Inc.Private | 1 asset: 1 Ph 2 | ENT-01Phase 2 · Parkinson's DiseasePartial signal | None on record |
 Enveda TherapeuticsPrivate | 1 asset: 1 Ph 2 | ENV-294Phase 2 · Asthma | Dec 2026ENV-294 · Phase 2 |
 Enyo PharmaPrivate | 1 asset: 1 Ph 2 | VonafexorPhase 2 · Chronic Kidney DiseasePartial signal | None on record |
 Enzychem Lifesciences183490 · KOSDAQ | 1 asset: 1 Ph 2 | MosedipimodPhase 2 · Atopic Dermatitis | Oct 2027Mosedipimod · Phase 2 |
 EpiBiologicsPrivate | 1 asset: 1 Ph 1 | EPI-326Phase 1 · Non-Small Cell Lung Cancer | Jul 2029EPI-326 · Phase 1 |
EpiDestinyPrivate | 1 asset: 1 Ph 2 | Decitabine/Tetrahydrouridine (NDec)Phase 2 · Sickle Cell Disease | None on record |
 EpiEndo PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | glasmacinalPhase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | None on record |
 EpkinPrivate | 1 asset: 1 Ph 1 | OKN4395Phase 1 · Non-Small Cell Lung Cancer | Jul 2028OKN4395 · Phase 1 |
 Everest Medicines (Beijing) Co., Ltd.1952 · HKEX | 1 asset: 1 Ph 2 | EVM14Phase 1/2 · Non-Small Cell Lung Cancer | Jul 2028EVM14 · Phase 1 |
 EvommuneEVMN · NYSE | 1 asset: 1 Ph 2 | EVO756Phase 2 · Migraine | Oct 2027EVO756 · Phase 2 |
 Evopoint Biosciences Inc.Private | 1 asset: 1 Ph 2 | ASP546CPhase 1/2 · Non-Small Cell Lung Cancer | None on record |
 FUJIFILM Toyama ChemicalPrivate | 1 asset: 1 Ph 3 | IguratimodPhase 3 · Rheumatoid Arthritis | None on record |
 Faron Pharmaceuticals LtdPrivate | 1 asset: 1 Ph 2 | BexmarilimabPhase 1/2 · Acute Myeloid Leukemia | Mar 2027Bexmarilimab · Phase 1/2 |
 Ferrer InternacionalPrivate | 1 asset: 1 Ph 2 | CNIC-Ferrer polypillPhase 2 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
| 1 asset: 1 Ph 1 | INN805Phase 1 · Non-Small Cell Lung Cancer | Dec 2026INN805 · Phase 1 | |
 Foresee Pharmaceuticals6576 · TPEx | 1 asset: 1 Ph 2 | MirivadelgatPhase 2 · Hypertension | Feb 2028Mirivadelgat · Phase 2 |
 Formycon AGFYB · Xetra | 1 asset: 1 approved | Approved assets only | None on record |
 Fortis Therapeutics, Inc.Private | 1 asset: 1 Ph 1 | FOR46Phase 1 · Multiple MyelomaWeak signal | None on record |
| 1 asset: 1 Ph 2 | FMC-376Phase 1/2 · Non-Small Cell Lung Cancer | Oct 2027FMC-376 · Phase 1/2 | |
| 1 asset: 1 Ph 2 | FF-10832Phase 2 · Non-Small Cell Lung Cancer | May 2029FF-10832 · Phase 2 | |
 Fulcrum TherapeuticsFULC · Nasdaq | 1 asset: 1 Ph 2 | LosmapimodPhase 2 · Facioscapulohumeral Muscular Dystrophy | None on record |
 G2GBio, Inc.Private | 1 asset: 1 Ph 1 | GB-5001Phase 1 · Alzheimer's DiseaseWeak signal | None on record |
| 1 asset: 1 Ph 2 | SUL-238Phase 2 · Parkinson's Disease | None on record | |
 GI Cell, Inc.Private | 1 asset: 1 Ph 2 | GIC-102Phase 1/2 · Multiple MyelomaWeak signal | None on record |
 GRI Bio, Inc.GRI · Nasdaq | 1 asset: 1 other | GRI-0803Systemic Lupus Erythematosus | None on record |
 GV20 TherapeuticsPrivate | 1 asset: 1 Ph 2 | GV20-0251Phase 2 · Non-Small Cell Lung Cancer | 15 Dec 2026GV20-0251 · Phase 1/2 |
 GW PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | 1 Aug 2027Cannabidiol (Epidiolex) · Approved |
 Gain Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | GT-02287Phase 2 · Parkinson's Disease | 30 Jun 2028GT-02287 · Phase 2 |
 Galmed Pharmaceuticals Ltd.EOCN · Nasdaq | 1 asset: 1 Ph 3 | AramcholPhase 3 · Metabolic Dysfunction-Associated Steatohepatitis | None on record |
GeNOPrivate | 1 asset: 1 Ph 2 | Inhaled Nitric Oxide (GeNO NITROSYL platform)Phase 2 | None on record |
 Gedeon RichterRICHT · Budapest Stock Exchange | 1 asset: 1 approved | Approved assets only | 15 Dec 2026Cariprazine (Vraylar) · Phase 3 |
 GemVax & KAEL082270 · KOSDAQ | 1 asset: 1 Ph 3 | GV1001Phase 3 · Alzheimer's DiseasePartial signal | None on record |
 GeneCradle IncPrivate | 1 asset: 1 Ph 1 | GC304Phase 1 · Atherosclerotic Cardiovascular Disease | Dec 2026GC304 · Phase 1 |
 GeneCraft Inc.Private | 1 asset: 1 Ph 1 | RX001Phase 1 · Non-Small Cell Lung Cancer | None on record |
 Genelux CorporationGNLX · Nasdaq | 1 asset: 1 Ph 3 | Olvimulogene nanivacirepvecPhase 3 · Ovarian Cancer | Dec 2026Olvimulogene nanivacirepvec · Phase 3 |
| 1 asset: 1 Ph 1 | GM101Phase 1 · Parkinson's Disease | 17 Feb 2027GM101 · Phase 1 | |
 Genenta Science S.p.A.GNTA · Nasdaq | 1 asset: 1 Ph 2 | TemferonPhase 1/2 · Glioblastoma | None on record |
 Genentech (Roche Group)Private | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 approved | Approved assets only | May 2027Lovotibeglogene autotemcel (Lyfgenia) · Phase 3 | |
 Genovate Biotechnology4130 · TPEx | 1 asset: 1 Ph 3 | PMR (cilostazol ER)Phase 3 · Atherosclerotic Cardiovascular DiseaseWeak signal | None on record |
 Genprex, Inc.GNPX · Nasdaq | 1 asset: 1 Ph 2 | Quaratusugene OzeplasmidPhase 1/2 · Non-Small Cell Lung Cancer | Dec 2027Quaratusugene Ozeplasmid · Phase 1/2 |
 Genrix Bio688443 · SSE STAR Market | 1 asset: 1 Ph 3 | GR1803Phase 3 · Multiple MyelomaWeak signal | 12 May 2027GR1803 · Phase 2 |
 Gensco Laboratories LLCPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Geron CorporationGERN · Nasdaq | 1 asset: 1 approved | Approved assets only | Feb 2027Imetelstat · Phase 1 |
 Gloria BiosciencesPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 GluBio Therapeutics Inc.Private | 1 asset: 1 Ph 1 | GLB-001Phase 1 · Acute Myeloid Leukemia | None on record |
 Gossamer BioGOSS · Nasdaq | 1 asset: 1 Ph 3 | SeralutinibPhase 3 · Pulmonary Arterial Hypertension | Dec 2026Seralutinib · Phase 3 |
 Grace TherapeuticsGRCE · Nasdaq | 1 asset: 1 Ph 3 | NimodipinePhase 3 · Subarachnoid Hemorrhage | None on record |
 Grey Wolf TherapeuticsPrivate | 1 asset: 1 Ph 2 | GRWD5769Phase 1/2 · Non-Small Cell Lung Cancer | 30 Apr 2027GRWD5769 · Phase 1/2 |
 Grit BiotechnologyPrivate | 1 asset: 1 Ph 1 | GT737Phase 1 · Acute Myeloid Leukemia | Jun 2030GT737 · Phase 1 |
 Guangdong Raynovent BiotechPrivate | 1 asset: 1 Ph 3 | RAY1225Phase 3 · Obesity | 14 Oct 2026RAY1225 · Phase 1 |
| 1 asset: 1 Ph 2 | BG1805Phase 1/2 · Acute Myeloid Leukemia | Mar 2027BG1805 · Phase 1/2 | |
| 1 asset: 1 Ph 1 | HNC364Phase 1 · Parkinson's DiseaseWeak signal | 31 Dec 2026HNC364 · Phase 1 | |
| 1 asset: 1 Ph 1 | MN-08Phase 1 | 30 Mar 2028MN-08 · Phase 1 | |
| 1 asset: 1 Ph 2 | XJN010Phase 2 · Parkinson's Disease | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).